Piper Sandler Maintains Overweight on IO Biotech, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has reiterated an Overweight rating on IO Biotech (NASDAQ:IOBT) and maintained a price target of $10.
September 03, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on IO Biotech, maintaining a $10 price target, indicating confidence in the company's potential.
The reaffirmation of an Overweight rating and a $10 price target by Piper Sandler suggests a positive outlook for IO Biotech. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100